NO784025L - Antiperspirant. - Google Patents

Antiperspirant.

Info

Publication number: NO784025L
Authority: NO; Norway
Prior art keywords: antiperspirant; lidocaine; prilocaine; active; placebo
Prior art date: 1977-12-01

Application number

NO784025A

Other languages

English (en)

Norwegian (no)

Inventor

Benrdt Fredrik Julius Broberg

Hans Christer Arvid Evers

Lennart August Albert Juhlin

Original Assignee

Astra Gemaverken Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-12-01

Filing date

1978-11-30

Publication date

1979-06-05

1978-11-30 Application filed by Astra Gemaverken Ab filed Critical Astra Gemaverken Ab

1979-06-05 Publication of NO784025L publication Critical patent/NO784025L/no

Links

239000003213 antiperspirant Substances 0.000 title claims description 25
230000001166 anti-perspirative effect Effects 0.000 title claims description 24
239000000839 emulsion Substances 0.000 claims description 20
150000001875 compounds Chemical class 0.000 claims description 18
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 15
BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 15
MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 15
229960001807 prilocaine Drugs 0.000 claims description 14
229960004194 lidocaine Drugs 0.000 claims description 11
239000000203 mixture Substances 0.000 claims description 10
239000013543 active substance Substances 0.000 claims description 8
239000003589 local anesthetic agent Substances 0.000 claims description 8
INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims description 8
LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 7
VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims description 7
229960005274 benzocaine Drugs 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
229960003150 bupivacaine Drugs 0.000 claims description 6
239000003995 emulsifying agent Substances 0.000 claims description 6
229960003976 etidocaine Drugs 0.000 claims description 6
-1 kinisocaine Chemical compound 0.000 claims description 6
229960002409 mepivacaine Drugs 0.000 claims description 6
229960002372 tetracaine Drugs 0.000 claims description 6
GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 6
UXAWFWFJXIANHZ-UHFFFAOYSA-N 1-[2-[2-[di(propan-2-yl)amino]ethoxy]phenyl]butan-1-one Chemical compound CCCC(=O)C1=CC=CC=C1OCCN(C(C)C)C(C)C UXAWFWFJXIANHZ-UHFFFAOYSA-N 0.000 claims description 5
229950001903 ketocaine Drugs 0.000 claims description 5
239000002562 thickening agent Substances 0.000 claims description 5
229950002569 trimecaine Drugs 0.000 claims description 5
229960001747 cinchocaine Drugs 0.000 claims description 4
PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims description 4
OECNHRSNFLARHZ-UHFFFAOYSA-N n-[2-(2-butoxyphenoxy)ethyl]-n-propan-2-ylpropan-2-amine Chemical compound CCCCOC1=CC=CC=C1OCCN(C(C)C)C(C)C OECNHRSNFLARHZ-UHFFFAOYSA-N 0.000 claims description 4
GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 claims description 4
230000001078 anti-cholinergic effect Effects 0.000 claims description 3
HQFWVSGBVLEQGA-UHFFFAOYSA-N 4-aminobenzoic acid 3-(dibutylamino)propyl ester Chemical compound CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1 HQFWVSGBVLEQGA-UHFFFAOYSA-N 0.000 claims description 2
230000001466 anti-adreneric effect Effects 0.000 claims description 2
229960003369 butacaine Drugs 0.000 claims description 2
229960003502 oxybuprocaine Drugs 0.000 claims description 2
CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 claims description 2
229950006609 tolycaine Drugs 0.000 claims description 2
UDKICLZCJWQTLS-UHFFFAOYSA-N tolycaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C(=O)OC UDKICLZCJWQTLS-UHFFFAOYSA-N 0.000 claims description 2
229960001290 butanilicaine Drugs 0.000 claims 2
VWYQKFLLGRBICZ-UHFFFAOYSA-N butanilicaine Chemical compound CCCCNCC(=O)NC1=C(C)C=CC=C1Cl VWYQKFLLGRBICZ-UHFFFAOYSA-N 0.000 claims 2
229940068196 placebo Drugs 0.000 description 20
239000000902 placebo Substances 0.000 description 20
230000000694 effects Effects 0.000 description 12
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 8
230000036592 analgesia Effects 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
210000004243 sweat Anatomy 0.000 description 7
238000012360 testing method Methods 0.000 description 7
239000002253 acid Substances 0.000 description 6
150000007513 acids Chemical class 0.000 description 6
238000007789 sealing Methods 0.000 description 6
230000002500 effect on skin Effects 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
239000000463 material Substances 0.000 description 4
238000000034 method Methods 0.000 description 4
210000000106 sweat gland Anatomy 0.000 description 4
230000035900 sweating Effects 0.000 description 4
WZSPWMATVLBWRS-UHFFFAOYSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;n-(2-methylphenyl)-2-(propylamino)propanamide Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C WZSPWMATVLBWRS-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229920002125 Sokalan® Polymers 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000011282 treatment Methods 0.000 description 3
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
210000000245 forearm Anatomy 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
230000036407 pain Effects 0.000 description 2
ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
229960004919 procaine Drugs 0.000 description 2
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920003043 Cellulose fiber Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
208000012266 Needlestick injury Diseases 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
229940105270 carbocaine Drugs 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229940097598 citanest Drugs 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000001834 epinephrinelike Effects 0.000 description 1
239000000374 eutectic mixture Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000001061 forehead Anatomy 0.000 description 1
239000000417 fungicide Substances 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
229960004068 hexachlorophene Drugs 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
229940071870 hydroiodic acid Drugs 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
208000021822 hypotensive Diseases 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229940106885 marcaine Drugs 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
229910052761 rare earth metal Inorganic materials 0.000 description 1
150000002910 rare earth metals Chemical class 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000032258 transport Effects 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000008096 xylene Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052726 zirconium Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Birds (AREA)
Epidemiology (AREA)
Cosmetics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO784025A 1977-12-01 1978-11-30 Antiperspirant. NO784025L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE7713617A SE7713617L (sv)	1977-12-01	1977-12-01	Antitranspirationsmedel

Publications (1)

Publication Number	Publication Date
NO784025L true NO784025L (no)	1979-06-05

Family

ID=20333073

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO784025A NO784025L (no)	1977-12-01	1978-11-30	Antiperspirant.

Country Status (8)

Country	Link
EP (1)	EP0002426B1 (fi)
JP (1)	JPS55105613A (fi)
CA (1)	CA1113399A (fi)
DE (1)	DE2861141D1 (fi)
DK (1)	DK538878A (fi)
FI (1)	FI783642A (fi)
NO (1)	NO784025L (fi)
SE (1)	SE7713617L (fi)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3356284A (en) *	1983-11-30	1985-06-06	Coopers Animal Health Australia Limited	Roll-on applications of topical medicaments
US6528086B2 (en) *	1999-09-28	2003-03-04	Zars, Inc.	Methods and apparatus for drug delivery involving phase changing formulations
US20030124174A1 (en) *	2001-10-25	2003-07-03	Endo Pharmaceuticals, Inc	Method for treating non-neuropathic pain
US8907153B2 (en)	2004-06-07	2014-12-09	Nuvo Research Inc.	Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US8741332B2 (en)	2004-06-07	2014-06-03	Nuvo Research Inc.	Compositions and methods for dermally treating neuropathic pain
US8741333B2 (en)	2004-06-07	2014-06-03	Nuvo Research Inc.	Compositions and methods for treating dermatitis or psoriasis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2614963A (en) *	1951-01-10	1952-10-21	Kendall & Co	Keratin exfoliative compositions
US3079299A (en) *	1959-11-16	1963-02-26	Gen Aerosol Corp	Self-propelling medicinal ointment composition containing polyethylene and method ofapplication
GB1213295A (en) *	1967-04-27	1970-11-25	Boots Pure Drug Co Ltd	Improvements in therapeutic compositions for topical application
IL32576A (en) *	1968-07-19	1972-05-30	Ciba Geigy Ag	Antihaemorrhoidally active preparation for rectal administration containing a glucofuranoside compound
FR2150613A1 (en) *	1971-08-31	1973-04-13	Howard Alfred	Dibucaine aerosol compsn - for prevention of premature ejaculation

1977
- 1977-12-01 SE SE7713617A patent/SE7713617L/xx not_active Application Discontinuation
1978
- 1978-11-28 FI FI783642A patent/FI783642A/fi unknown
- 1978-11-30 DK DK538878A patent/DK538878A/da not_active Application Discontinuation
- 1978-11-30 CA CA317,154A patent/CA1113399A/en not_active Expired
- 1978-11-30 JP JP14729778A patent/JPS55105613A/ja active Pending
- 1978-11-30 NO NO784025A patent/NO784025L/no unknown
- 1978-12-01 EP EP78850022A patent/EP0002426B1/en not_active Expired
- 1978-12-01 DE DE7878850022T patent/DE2861141D1/de not_active Expired

Also Published As

Publication number	Publication date
SE7713617L (sv)	1979-06-02
DK538878A (da)	1979-06-02
CA1113399A (en)	1981-12-01
EP0002426B1 (en)	1981-10-07
DE2861141D1 (en)	1981-12-17
JPS55105613A (en)	1980-08-13
EP0002426A1 (en)	1979-06-13
FI783642A (fi)	1979-06-02

Publication	Publication Date	Title
US4562060A (en)	1985-12-31	Local anesthetic mixture for topical application, process for its preparation, as well as method for obtaining local anesthesia
US3472931A (en)	1969-10-14	Percutaneous absorption with lower alkyl amides
KR100764156B1 (ko)	2007-10-08	국소 마취제의 국소 투여를 위한 피내 침투제
JP4759902B2 (ja)	2011-08-31	瘢痕を治療する方法と組成物
US5738856A (en)	1998-04-14	Skin care preparation and method
JP2003509164A (ja)	2003-03-11	単純疱疹のような障害組織を治療するための、振動させて抗感染性組成物を送達させるシステム
RU94045258A (ru)	1996-10-20	Косметическая или дерматологическая композиция для одновременного лечения поверхностных и глубоких слоев кожи и ее применение
WO2002049603A1 (en)	2002-06-27	Compositions for prevention and alleviation of skin wrinkles
Biro et al.	1997	Comparison of topical anaesthesia methods for venous cannulation in adults
McCafferty et al.	1988	Comparative in vivo and in vitro assessment of the percutaneous absorption of local anaesthetics
Marples et al.	1974	Methods for evaluating topical antibacterial agents on human skin
US3953599A (en)	1976-04-27	Compositions for topical application to animal tissue and method of enhancing penetration thereof
NO784025L (no)	1979-06-05	Antiperspirant.
RU2197273C2 (ru)	2003-01-27	Приспособление в виде пластыря для местного нанесения противоугревого состава и способ его изготовления
Statham et al.	1984	Short‐contact dithranol therapy—a comparison with the Ingram regime
JP2009523703A (ja)	2009-06-25	アルテミシニン及びその誘導体を使用する良性色素性ホクロ（母斑）の処置及び予防
JP5138299B2 (ja)	2013-02-06	皮膚用剤
US20040001791A1 (en)	2004-01-01	Composition, method of use, and devices for the treatment of onychomycosis
US9757360B2 (en)	2017-09-12	Pharmaceutical composition comprising a ryanodine receptor antagonist for facilitating wound healing
CA2039643C (en)	2002-09-10	Anti-wart composition
BOWE	1960	Primary excision in third degree burns
US20060165813A1 (en)	2006-07-27	Topical composition for treatment of skin disorders
TWI327476B (fi)	2010-07-21
Bennett et al.	1979	Etidocaine, a new local anesthetic
RU1822769C (ru)	1993-06-23	Средство дл стимулировани роста волос